Industry: Biotechnology (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-09-05 | Amended | $14,999,999 | Unknown | Equity Only | SEC link | |
| 2025-07-03 | Amended | $31,024,760 | $1,735,362 | Equity Only | 06b | SEC link |
| 2025-07-03 | New | $14,700,754 | $14,700,754 | Equity Only | 06b | SEC link |
| 2024-09-23 | Amended | $29,289,398 | $9,149,604 | Equity Only | 06b | SEC link |
| 2024-05-10 | Amended | $20,139,794 | $7,176,295 | Equity Only | 06b | SEC link |
| 2023-12-05 | New | $12,963,499 | $12,963,499 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| Martha Aronson | Director |
| Kurt Azarbarzin | Director |
| Mike Frazzette | Director |
| Michael Frazzette | Director |
| Derek Herrera | Director, Executive |
| Kevin Herschberger | Executive |
| Kevin Hershberger | Executive |
| Sherman Williams | Director |